Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine

Sumithra J Mandrekar, Daniel J. Sargent

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

In the current era of stratified medicine and biomarker-driven therapies, the focus has shifted from predictions based on the traditional anatomic staging systems to guide the choice of treatment for an individual patient to an integrated approach using the genetic makeup of the tumor and the genotype of the patient. The clinical trial designs utilized in the developmental pathway for biomarkers and biomarker-directed therapies from discovery to clinical practice are rapidly evolving. While several issues need careful consideration, two critical issues that surround the validation of biomarkers are the choice of the clinical trial design (which is based on the strength of the preliminary evidence and marker prevalence), and biomarker assay related issues surrounding the marker assessment methods such as the reliability and reproducibility of the assay. In this review, we focus on trial designs aiming at personalized medicine in the context of early phase trials for initial marker validation, as well as in the context of larger definitive trials. Designs for biomarker validation are broadly classified as retrospective (i.e., using data from previously well-conducted randomized controlled trials (RCTs) versus prospective (enrichment, all-comers, hybrid or adaptive). We believe that the systematic evaluation and implementation of these design strategies are essential to accelerate the clinical validation of biomarker guided therapy.

Original languageEnglish (US)
Article number14
JournalChinese Clinical Oncology
Volume3
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Precision Medicine
Drug Design
Biomarkers
Clinical Trials
Therapeutics
Randomized Controlled Trials
Genotype
Medicine

Keywords

  • Adaptive design
  • All-comers design
  • Biomarker
  • Enrichment design
  • Hybrid design
  • Randomized controlled trial (RCT)

ASJC Scopus subject areas

  • Oncology

Cite this

Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. / Mandrekar, Sumithra J; Sargent, Daniel J.

In: Chinese Clinical Oncology, Vol. 3, No. 2, 14, 2014.

Research output: Contribution to journalReview article

@article{180c5ff6d1dd413fb589292b33cbdf7f,
title = "Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine",
abstract = "In the current era of stratified medicine and biomarker-driven therapies, the focus has shifted from predictions based on the traditional anatomic staging systems to guide the choice of treatment for an individual patient to an integrated approach using the genetic makeup of the tumor and the genotype of the patient. The clinical trial designs utilized in the developmental pathway for biomarkers and biomarker-directed therapies from discovery to clinical practice are rapidly evolving. While several issues need careful consideration, two critical issues that surround the validation of biomarkers are the choice of the clinical trial design (which is based on the strength of the preliminary evidence and marker prevalence), and biomarker assay related issues surrounding the marker assessment methods such as the reliability and reproducibility of the assay. In this review, we focus on trial designs aiming at personalized medicine in the context of early phase trials for initial marker validation, as well as in the context of larger definitive trials. Designs for biomarker validation are broadly classified as retrospective (i.e., using data from previously well-conducted randomized controlled trials (RCTs) versus prospective (enrichment, all-comers, hybrid or adaptive). We believe that the systematic evaluation and implementation of these design strategies are essential to accelerate the clinical validation of biomarker guided therapy.",
keywords = "Adaptive design, All-comers design, Biomarker, Enrichment design, Hybrid design, Randomized controlled trial (RCT)",
author = "Mandrekar, {Sumithra J} and Sargent, {Daniel J.}",
year = "2014",
doi = "10.3978/j.issn.2304-3865.2014.05.03",
language = "English (US)",
volume = "3",
journal = "Chinese Clinical Oncology",
issn = "2304-3865",
publisher = "Society for Translational Medicine (STM)",
number = "2",

}

TY - JOUR

T1 - Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine

AU - Mandrekar, Sumithra J

AU - Sargent, Daniel J.

PY - 2014

Y1 - 2014

N2 - In the current era of stratified medicine and biomarker-driven therapies, the focus has shifted from predictions based on the traditional anatomic staging systems to guide the choice of treatment for an individual patient to an integrated approach using the genetic makeup of the tumor and the genotype of the patient. The clinical trial designs utilized in the developmental pathway for biomarkers and biomarker-directed therapies from discovery to clinical practice are rapidly evolving. While several issues need careful consideration, two critical issues that surround the validation of biomarkers are the choice of the clinical trial design (which is based on the strength of the preliminary evidence and marker prevalence), and biomarker assay related issues surrounding the marker assessment methods such as the reliability and reproducibility of the assay. In this review, we focus on trial designs aiming at personalized medicine in the context of early phase trials for initial marker validation, as well as in the context of larger definitive trials. Designs for biomarker validation are broadly classified as retrospective (i.e., using data from previously well-conducted randomized controlled trials (RCTs) versus prospective (enrichment, all-comers, hybrid or adaptive). We believe that the systematic evaluation and implementation of these design strategies are essential to accelerate the clinical validation of biomarker guided therapy.

AB - In the current era of stratified medicine and biomarker-driven therapies, the focus has shifted from predictions based on the traditional anatomic staging systems to guide the choice of treatment for an individual patient to an integrated approach using the genetic makeup of the tumor and the genotype of the patient. The clinical trial designs utilized in the developmental pathway for biomarkers and biomarker-directed therapies from discovery to clinical practice are rapidly evolving. While several issues need careful consideration, two critical issues that surround the validation of biomarkers are the choice of the clinical trial design (which is based on the strength of the preliminary evidence and marker prevalence), and biomarker assay related issues surrounding the marker assessment methods such as the reliability and reproducibility of the assay. In this review, we focus on trial designs aiming at personalized medicine in the context of early phase trials for initial marker validation, as well as in the context of larger definitive trials. Designs for biomarker validation are broadly classified as retrospective (i.e., using data from previously well-conducted randomized controlled trials (RCTs) versus prospective (enrichment, all-comers, hybrid or adaptive). We believe that the systematic evaluation and implementation of these design strategies are essential to accelerate the clinical validation of biomarker guided therapy.

KW - Adaptive design

KW - All-comers design

KW - Biomarker

KW - Enrichment design

KW - Hybrid design

KW - Randomized controlled trial (RCT)

UR - http://www.scopus.com/inward/record.url?scp=84926014085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926014085&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2304-3865.2014.05.03

DO - 10.3978/j.issn.2304-3865.2014.05.03

M3 - Review article

VL - 3

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

SN - 2304-3865

IS - 2

M1 - 14

ER -